Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have a diagnosis of rheumatoid arthritis based on the American College of Rheumatology Association~* The subject has active disease at both Screening and Baseline, as defined:~  * ≥4 joints tender or painful on motion, AND~ * ≥4 joints swollen;~* The subject must have at least one knee, one elbow, one wrist or two metacarpophalangeal joints with active synovitis suitable for biopsy by the shaver technique~Exclusion Criteria:~* No arthroscopy should have been performed in the past 3 months in the same joint that is to be biopsied in this study.~* No intra-articular steroids should have been injected in the joint to be biopsied in this study in the previous 3 months.~* Subjects with evidence of hematopoietic disorders or evidence of hemoglobin levels \< 9.0 gm/dL or hematocrit \< 30 % at screening visit or within the 3 months prior to baseline synovial biopsy.~* An absolute white blood cell (WBC) count of \< 3.0 x 109/L (\<3000/mm3) or absolute neutrophil count of \<1.2 X 109/L (\<1200/mm3) at screening visit or within the 3 months prior to baseline synovial biopsy.~* Thrombocytopenia, as defined by a platelet count \<100 x 109/L (\< 100,000/mm3) at screening visit or within the 3 months prior to baseline synovial biopsy.~* Estimated GFR less than 40 ml/min based on Cockcroft Gault calculation .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CP-690,550 + methotrexate (Type: EXPERIMENTAL): None
- Placebo + methotrexate (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).